Qiagen (QGEN) investor relations material

Board and Leadership Updates

• Proxy for the upcoming AGM includes proposals for new share buybacks and board changes.

• Approval sought for up to 10% open market buybacks and $200 million synthetic buyback, following a $500 million buyback in January.

• Supervisory Board refresh includes a new member from West Pharma and the founder stepping down to honorary chairman.

• CEO search ongoing, with interim leadership expected until a new CEO is announced, likely in H2; no shortage of CEO candidates and strategic review continues.

Capital Allocation and Shareholder Returns

• Dividend increased by 40% to $0.35 per share, reflecting confidence in cash generation.

• Continued commitment to share buybacks, dividend growth, and bolt-on acquisitions.

• Sufficient cash flow and leverage to support all capital deployment priorities.

• At least $1 billion in shareholder returns planned for 2024–2028, excluding M&A.

Financial Performance and Guidance

• Q1 results met expectations except for a $10 million shortfall, mainly due to QuantiFERON immigration-related business.

• Full-year guidance revised, removing $30 million from U.S. immigration and $5 million from Middle East QuantiFERON revenues.

• Non-immigration QuantiFERON business expected to grow at 5-6%, with inventory reset likely by H2.

• Operating margin target reaffirmed at 29.5% for 2024, with a long-term goal of 31% by 2028.

• Q1 2026 net sales reached $492 million (+2% actual, -1% CER), with adjusted diluted EPS of $0.54, in line with outlook.